Measuring Outcomes of Activity in Intensive Care (MOSAIC)

January 19, 2024 updated by: Wes Ely, Vanderbilt University Medical Center

Long-term Outcomes of Physical Activity in Older Adults With Critical Illness

Millions of older adults are hospitalized for a critical illness each year and although they are more likely than ever to survive this illness, they commonly face significant morbidity in the form of disabilities in basic self-care activities and in mobility in the months and years afterwards. A better understanding of the underlying risk factors for disability following critical illness is greatly needed, including the effect that activity during hospitalization may have on these outcomes. Therefore, we designed the Measuring OutcomeS of Activity in Intensive Care (MOSAIC) observational study to evaluate the relationship between activity (measured more rigorously than in prior investigations) and disability, physical function, and cognitive function in survivors of critical illness 3 and 12 months after ICU discharge.

Study Overview

Detailed Description

The MOSAIC observational study will measure activity in critically ill patients for up to 28 days in the hospital using two different, objective measures, a clinical mobility scale and accelerometry. We will evaluate the independent association between activity and outcomes 3 and 12 months after ICU discharge. Specifically, Aim 1 will determine the relationship between activity and disability in ADLs and mobility. Aim 2a will determine the relationship between activity and physical and cognitive function. Aim 2b will evaluate physical and cognitive function as mediators of long-term disability. Aim 3a will determine the relationship between activity and biomarkers of inflammation and coagulation. Aim 3b will determine the relationship between these biomarkers of inflammation and coagulation and disability, physical and cognitive function.

Study Type

Observational

Enrollment (Estimated)

312

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ohio
      • Columbus, Ohio, United States, 43210
        • The Ohio State University Medical Center
    • Tennessee
      • Nashville, Tennessee, United States, 37212
        • Vanderbilt University Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult patients with medical or surgical critical illness

Description

Inclusion Criteria:

  1. adult patients (≥18 years old),
  2. in a medical or surgical ICU at Vanderbilt University Medical Center or The Ohio State University Medical Center, and
  3. are being treated for respiratory failure or shock.

Exclusion Criteria:

  1. Rapidly resolving organ failure criteria, indicated by planned immediate discontinuation of mechanical ventilation, NIPPV, and/or vasopressors at the time of screening for study enrollment, such that the patient will no longer meet inclusion criteria.
  2. Cumulative hospital days (ICU plus non-ICU) of five or greater in the last 30 days prior to meeting all inclusion criteria.
  3. Inability to live independently at baseline due to acquired or congenital disabling, physical, cognitive or mental health disorder requiring institutionalization (e.g., nursing home, skilled nursing facility, group home, long-term acute care hospital, rehab facility) or any patient who resides outside an institution with an inability to walk without the assistance of another person (e.g., patients with quadriplegia, paraplegia, double amputees, those with residual paralysis from stroke).
  4. Acute or subacute severe neurologic (e.g., stroke anoxic injury, spinal cord injury) that is expected to prevent the patient from living independently after hospital discharge.
  5. Body mass index >50
  6. Active substance abuse or psychotic disorder (e.g., schizophrenia or schizo-affective disorder), recent (within the past 6 months) serious suicidal gesture necessitating hospitalization
  7. Blindness, deafness, or inability to understand English that will preclude follow-up evaluation. Patients with laryngectomies and those with hearing impairments are eligible for enrollment if their medical condition permits them to communicate with research staff.
  8. Expected death within 24 hours of enrollment or lack of commitment to aggressive treatment by family or the medical team (e.g., likely to withdraw life support measures within 24 hours of screening).
  9. Prisoners
  10. Patients who live further than 200 miles from an enrolling center and who do not regularly visit the area.
  11. Patients who are homeless and have no secondary contact person available
  12. Current enrollment in a study that does not allow co-enrollment
  13. Inability to obtain informed consent from the patient or an authorized representative within 72 hours of meeting all inclusion criteria for the following reasons:

    1. Attending physician refusal
    2. Patient and/or surrogate refusal
    3. 72-hour period of eligibility was exceeded before the patient was screened
    4. Patient unable to consent and no surrogate available within 72 hours of meeting all inclusion criteria
  14. Confirmed or suspected COVID-19 per local guidelines at the time of screen.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Adults (≥18 years old) with critical illness

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Precipitating Events Project Disability Questionnaire
Time Frame: 12 months
Questionnaire assessment of activities of daily living and mobility
12 months
Life Space Assessment Questionnaire
Time Frame: 12 months
Questionnaire assessment of activities of community mobility
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Precipitating Events Project Disability Questionnaire
Time Frame: 3 months
Questionnaire assessment of activities of daily living and mobility
3 months
Life Space Assessment Questionnaire
Time Frame: 3 months
Questionnaire assessment of activities of community mobility
3 months
Survival
Time Frame: 30, 90, and 365 days
Proportion of patients surviving at 30, 90, and 365 days
30, 90, and 365 days
Ventilator-free days
Time Frame: out of 28 days
Days alive and free of mechanical ventilation
out of 28 days
Delirium and coma-free days
Time Frame: out of 28 days
Days alive and without delirium or coma
out of 28 days
ICU Length of Stay
Time Frame: up to 28 days
Days spent in the ICU during the index hospitalization
up to 28 days
Hospital Length of Stay
Time Frame: up to 28 days
Days spent in the hospital during the index hospitalization
up to 28 days
Short Physical Performance Battery
Time Frame: 3 months
Performance Measure of Physical Function
3 months
Short Physical Performance Battery
Time Frame: 12 months
Performance Measure of Physical Function
12 months
Handgrip Dynamometry
Time Frame: 3 months
Performance Measure of Muscle Strength
3 months
Handgrip Dynamometry
Time Frame: 12 months
Performance Measure of Muscle Strength
12 months
Repeatable Battery for the Assessment of Neuropsychological Status
Time Frame: 3 months
Test of Global Cognition
3 months
Repeatable Battery for the Assessment of Neuropsychological Status
Time Frame: 12 months
Test of Global Cognition
12 months
Trail Making Test Parts A & B
Time Frame: 3 months
Test of Executive Function
3 months
Trail Making Test Parts A & B
Time Frame: 12 months
Test of Executive Function
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 27, 2017

Primary Completion (Actual)

February 1, 2022

Study Completion (Estimated)

December 31, 2024

Study Registration Dates

First Submitted

March 28, 2017

First Submitted That Met QC Criteria

April 11, 2017

First Posted (Actual)

April 14, 2017

Study Record Updates

Last Update Posted (Actual)

January 23, 2024

Last Update Submitted That Met QC Criteria

January 19, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sepsis

3
Subscribe